Report: GlobeImmune Delays IPO

Louisville, Colorado-based GlobeImmune has reportedly delayed its IPO, according to Fortune's Term Sheet. The reason for the delay was not given, however, the report said the company had scheduled the IPO for this week. The developer of biopharmaceuticals for treating cancer and infectious diseases had set its estimated pricing range at between $11.00 and $13.00 per share two weeks ago, which usually precedes the IPO pricing. GlobeImmune is venture backed by Celgene, HealthCare Ventures, Morgenthaler Partners, Wexford-Kappa Investors, Sequel Ventures, Lilly Ventures, and Medica Venture Partners.